Michael Lübbert


Ontology type: schema:Person     


Person Info

NAME

Michael

SURNAME

Lübbert

Publications in SciGraph latest 50 shown

  • 2022-08-22 The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation in BLOOD CANCER JOURNAL
  • 2022-06-16 Epigenetik von Tumoren in KOMPENDIUM INTERNISTISCHE ONKOLOGIE
  • 2022-04-27 First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2022-02-15 Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia in ADVANCES IN THERAPY
  • 2021-11-16 The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia in ADVANCES IN THERAPY
  • 2021-07-30 AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms in ONCOGENE
  • 2021-07-05 The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression in CELL DEATH & DISEASE
  • 2021-06-26 Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia in BMC MEDICAL GENOMICS
  • 2021-05-06 Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies in LEUKEMIA
  • 2021-04-28 Correction to: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients in CLINICAL EPIGENETICS
  • 2021-04-27 Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) in ANNALS OF HEMATOLOGY
  • 2021-04-12 Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients in CLINICAL EPIGENETICS
  • 2021-04-01 Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis in ANNALS OF HEMATOLOGY
  • 2021-03-13 Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab in ANNALS OF HEMATOLOGY
  • 2021-02-02 Erratum zu: Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020 in BEST PRACTICE ONKOLOGIE
  • 2021-02-01 Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction in COMMUNICATIONS BIOLOGY
  • 2021-01-04 Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020 in BEST PRACTICE ONKOLOGIE
  • 2020-11-10 Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report in ANNALS OF HEMATOLOGY
  • 2020-06-29 Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS in LEUKEMIA
  • 2020-06-16 Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia in ANNALS OF HEMATOLOGY
  • 2020-06-06 Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia in ANNALS OF HEMATOLOGY
  • 2020-04-03 Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation in NATURE COMMUNICATIONS
  • 2019-10-14 Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial in LEUKEMIA
  • 2019-08-28 Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML) in LEUKEMIA
  • 2019-05-30 Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors in BONE MARROW TRANSPLANTATION
  • 2019-03-05 Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML in LEUKEMIA
  • 2019-01-24 LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML in LEUKEMIA
  • 2018-11-23 Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation in LEUKEMIA
  • 2018-04-17 Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial in LEUKEMIA
  • 2018-02-12 Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells in NATURE MEDICINE
  • 2017-12-19 RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia in NATURE COMMUNICATIONS
  • 2017-10-31 Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) in ANNALS OF HEMATOLOGY
  • 2017-06-12 DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats in NATURE GENETICS
  • 2017-05-26 Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia in BLOOD CANCER JOURNAL
  • 2017-04-03 Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial in ANNALS OF HEMATOLOGY
  • 2017-03-22 The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia in ANNALS OF HEMATOLOGY
  • 2017-01-19 Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure in LEUKEMIA
  • 2017-01-18 Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia in LEUKEMIA
  • 2017-01-16 Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group in LEUKEMIA
  • 2017-01-05 Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy in ANNALS OF HEMATOLOGY
  • 2016-11-24 Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis in LEUKEMIA
  • 2016-10-03 All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study in ANNALS OF HEMATOLOGY
  • 2016-08-30 Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS in LEUKEMIA
  • 2016-07-04 Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group in LEUKEMIA
  • 2016-05-24 Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy in CLINICAL EPIGENETICS
  • 2016-05-02 Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS) in LEUKEMIA
  • 2016-04-11 Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia in LEUKEMIA
  • 2016-03-09 Azanucleoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia in EPIGENETICS - A DIFFERENT WAY OF LOOKING AT GENETICS
  • 2015-12-16 The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells in BMC CANCER
  • 2015-12-15 Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) in LEUKEMIA
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.7708.8", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.42505.36", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14095.39", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9122.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7497.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.33018.39", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14778.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5963.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6363.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.22937.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418936.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7692.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6582.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419801.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.452600.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.430269.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.19006.3e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412688.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4488.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.8348.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411327.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10392.39", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5361.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4567.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10423.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.13648.38", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5596.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.459950.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414473.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413591.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.470142.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.248762.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420036.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10417.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411544.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10388.32", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.500061.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410712.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5645.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7450.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.12380.38", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.469999.2", 
            "type": "Organization"
          }
        ], 
        "familyName": "L\u00fcbbert", 
        "givenName": "Michael", 
        "id": "sg:person.01153663723.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-10-01T07:17", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/person/person_831.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01153663723.53'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01153663723.53'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01153663723.53'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01153663723.53'


     

    This table displays all metadata directly associated to this object as RDF triples.

    102 TRIPLES      10 PREDICATES      54 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01153663723.53 schema:affiliation N389f98dfa2d84355babef8525fc9807d
    2 grid-institutes:grid.10388.32
    3 grid-institutes:grid.10392.39
    4 grid-institutes:grid.10417.33
    5 grid-institutes:grid.10423.34
    6 grid-institutes:grid.12380.38
    7 grid-institutes:grid.13648.38
    8 grid-institutes:grid.14095.39
    9 grid-institutes:grid.14778.3d
    10 grid-institutes:grid.19006.3e
    11 grid-institutes:grid.22937.3d
    12 grid-institutes:grid.240145.6
    13 grid-institutes:grid.248762.d
    14 grid-institutes:grid.33018.39
    15 grid-institutes:grid.410569.f
    16 grid-institutes:grid.410712.1
    17 grid-institutes:grid.411327.2
    18 grid-institutes:grid.411544.1
    19 grid-institutes:grid.412688.1
    20 grid-institutes:grid.413591.b
    21 grid-institutes:grid.414473.1
    22 grid-institutes:grid.418936.1
    23 grid-institutes:grid.419801.5
    24 grid-institutes:grid.420036.3
    25 grid-institutes:grid.42505.36
    26 grid-institutes:grid.430269.a
    27 grid-institutes:grid.4488.0
    28 grid-institutes:grid.452600.5
    29 grid-institutes:grid.4567.0
    30 grid-institutes:grid.459950.4
    31 grid-institutes:grid.469999.2
    32 grid-institutes:grid.470142.4
    33 grid-institutes:grid.500061.2
    34 grid-institutes:grid.5361.1
    35 grid-institutes:grid.5596.f
    36 grid-institutes:grid.5645.2
    37 grid-institutes:grid.5963.9
    38 grid-institutes:grid.6363.0
    39 grid-institutes:grid.6582.9
    40 grid-institutes:grid.7450.6
    41 grid-institutes:grid.7497.d
    42 grid-institutes:grid.7692.a
    43 grid-institutes:grid.8348.7
    44 grid-institutes:grid.9122.8
    45 schema:familyName Lübbert
    46 schema:givenName Michael
    47 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53
    48 schema:sdDatePublished 2022-10-01T07:17
    49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    50 schema:sdPublisher N36192f53e76040e8a6420fda6c1da5f8
    51 sgo:license sg:explorer/license/
    52 sgo:sdDataset persons
    53 rdf:type schema:Person
    54 N36192f53e76040e8a6420fda6c1da5f8 schema:name Springer Nature - SN SciGraph project
    55 rdf:type schema:Organization
    56 N389f98dfa2d84355babef8525fc9807d schema:affiliation grid-institutes:grid.7708.8
    57 sgo:isCurrent true
    58 rdf:type schema:OrganizationRole
    59 grid-institutes:grid.10388.32 schema:Organization
    60 grid-institutes:grid.10392.39 schema:Organization
    61 grid-institutes:grid.10417.33 schema:Organization
    62 grid-institutes:grid.10423.34 schema:Organization
    63 grid-institutes:grid.12380.38 schema:Organization
    64 grid-institutes:grid.13648.38 schema:Organization
    65 grid-institutes:grid.14095.39 schema:Organization
    66 grid-institutes:grid.14778.3d schema:Organization
    67 grid-institutes:grid.19006.3e schema:Organization
    68 grid-institutes:grid.22937.3d schema:Organization
    69 grid-institutes:grid.240145.6 schema:Organization
    70 grid-institutes:grid.248762.d schema:Organization
    71 grid-institutes:grid.33018.39 schema:Organization
    72 grid-institutes:grid.410569.f schema:Organization
    73 grid-institutes:grid.410712.1 schema:Organization
    74 grid-institutes:grid.411327.2 schema:Organization
    75 grid-institutes:grid.411544.1 schema:Organization
    76 grid-institutes:grid.412688.1 schema:Organization
    77 grid-institutes:grid.413591.b schema:Organization
    78 grid-institutes:grid.414473.1 schema:Organization
    79 grid-institutes:grid.418936.1 schema:Organization
    80 grid-institutes:grid.419801.5 schema:Organization
    81 grid-institutes:grid.420036.3 schema:Organization
    82 grid-institutes:grid.42505.36 schema:Organization
    83 grid-institutes:grid.430269.a schema:Organization
    84 grid-institutes:grid.4488.0 schema:Organization
    85 grid-institutes:grid.452600.5 schema:Organization
    86 grid-institutes:grid.4567.0 schema:Organization
    87 grid-institutes:grid.459950.4 schema:Organization
    88 grid-institutes:grid.469999.2 schema:Organization
    89 grid-institutes:grid.470142.4 schema:Organization
    90 grid-institutes:grid.500061.2 schema:Organization
    91 grid-institutes:grid.5361.1 schema:Organization
    92 grid-institutes:grid.5596.f schema:Organization
    93 grid-institutes:grid.5645.2 schema:Organization
    94 grid-institutes:grid.5963.9 schema:Organization
    95 grid-institutes:grid.6363.0 schema:Organization
    96 grid-institutes:grid.6582.9 schema:Organization
    97 grid-institutes:grid.7450.6 schema:Organization
    98 grid-institutes:grid.7497.d schema:Organization
    99 grid-institutes:grid.7692.a schema:Organization
    100 grid-institutes:grid.7708.8 schema:Organization
    101 grid-institutes:grid.8348.7 schema:Organization
    102 grid-institutes:grid.9122.8 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...